Cancer
Physicians Attack High Drug Costs
With the
cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100
influential cancer specialists from around the world have taken the unusual
step of banding together in hopes of persuading some leading pharmaceutical
companies to bring prices down.
By Andrew Pollack. In The New York Times
Skin Cancer
Linked to Higher Risk of Other Cancers
There’s
another reason for those at risk of skin cancer to stay vigilant about
protecting their health. Men and women with a history of non-melanoma skin
cancer are at a higher risk of developing breast and lung cancers in addition
to melanoma, compared to people without a skin cancer history
By Alexandra Sifferlin. In TIME
Cancer
survival rates improve but most people remain financially exposed
Medical
advance means more people diagnosed with cancer are surviving for longer,
according to new figures from the Office for National Statistics (ONS), but
relatively few people have any financial protection in place against the risk
of living with reduced earning power.
By Ian Cowie. In Telegraph.co.uk
(blog)
More than a
quarter of a century after the Chernobyl nuclear disaster, many children and
teenagers who developed thyroid cancer due to radiation are in complete or near
remission, according to a recent study accepted for publication in The
Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
In Science
Daily (press release)
Adrenalectomy
for Metastases Benefits Renal-Cancer Patients
Surgical
removal of adrenal metastases can offer long-term survival to selected cancer
patients — most notably those with renal-cell carcinoma — the results of a
large multicenter study indicate.
By Miriam E. Tucker. In Medscape
Les centres d'essais cliniques
précoces contre le cancer
Comme tous les médicaments, les
traitements contre le cancer doivent être évalués avoir de recevoir leur
autorisation de mise sur le marché. Mais très souvent le temps presse pour les
patients qui souhaitent bénéficier des techniques les plus avancées. C'est
ainsi que sont nés les centres d'essais cliniques précoces.
Dans France Info
Traitements ciblés contre le cancer:
l'eldorado risqué des grands labos
Proposer à des millions de patients
des "traitements ciblés" en fonction de mutations génétiques
retrouvées dans leur cancer, est devenu l'axe essentiel de la recherche pour
les grands laboratoires, pari qui n'est pas sans risque vu le temps et les
sommes colossales investis.
Par Olivier Thibault. Sur TV5
Aucun commentaire:
Enregistrer un commentaire